Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fexofenadine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 6/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | DRD3 | P35462 | 3/20 | 1.00 |
| ▸ | HTR2A | P28223 | 2/20 | 1.00 |
| ▸ | HTR2B | P41595 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | CNR1 | P21554 | 1/20 | 1.00 |
| ▸ | APEX1 | P27695 | 1/20 | 1.00 |
| ▸ | PDE4A | P27815 | 1/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 1/20 | 1.00 |
| ▸ | DRD2 | P14416 | 2/20 | 0.98 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.98 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.98 |
| ▸ | CYP2J2 | P51589 | 3/20 | 0.80 |
| ▸ | MEN1 | O00255 | 1/20 | 0.80 |
| ▸ | NPC1 | O15118 | 1/20 | 0.80 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.80 |
| ▸ | GMNN | O75496 | 1/20 | 0.80 |
| ▸ | USP2 | O75604 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fexofenadine SCHEMBL1972366 | 1.00 | HRH1 (1.00) | HRH1KCNH2LMNADRD3HTR2A | |
| Fexofenadine SCHEMBL7104316 | 1.00 | HRH1 (1.00) | HRH1KCNH2LMNADRD3HTR2A | |
| Fexofenadine SCHEMBL4900 | 1.00 | HRH1 (1.00) | HRH1KCNH2LMNADRD3HTR2A | |
| Fexofenadine SCHEMBL1561082 | 1.00 | HRH1 (1.00) | HRH1KCNH2LMNADRD3HTR2A | |
| Fexofenadine SCHEMBL3178320 | 1.00 | HRH1 (1.00) | HRH1KCNH2LMNADRD3HTR2A | |
| Fexofenadine SCHEMBL9943444 | 0.99 | HRH1 (0.98) | HRH1KCNH2LMNADRD3HTR2A | |
| Fexofenadine SCHEMBL16651410 | 0.99 | HRH1 (0.98) | HRH1KCNH2LMNADRD3HTR2A | |
| Fexofenadine SCHEMBL16652202 | 0.99 | HRH1 (0.98) | HRH1KCNH2LMNADRD3HTR2A | |
| Fexofenadine SCHEMBL1395674 | 0.99 | HRH1 (0.98) | HRH1KCNH2LMNADRD3HTR2A | |
| Fexofenadine SCHEMBL20531399 | 0.99 | HRH1 (0.98) | HRH1KCNH2LMNADRD3HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 26292 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6436924-B1 | — | — | None | — | — | US | claimed |
| US-20260139860-A1 | PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS | CENTRE FOR DIGESTIVE DISEASES (AU) | 2026-05-21 | — | — | US | claimed |
| CN-117209417-B | Fexofenadine Process for the preparation of isomers | 梯尔希（南京）药物研发有限公司 | 2026-05-15 | — | — | CN | claimed |
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | claimed |
| EP-4736841-A1 | A MUCOADHESIVE LAYER FOR BUCCAL ADMINISTRATION OF AN ACTIVE PHARMACEUTICAL INGREDIENT | IQ medical GmbH (DE) | 2026-05-06 | — | — | EP | claimed |
| EP-4734952-A1 | ORAL TABLET WITH IMPROVED UNIFORMITY OF CONTENT OF ACTIVES | Fertin Pharma A/S (DK) | 2026-05-06 | — | — | EP | claimed |
| US-20260118349-A1 | METHODS AND KITS FOR PREDICTING INFUSION REACTION RISK AND ANTIBODY MEDIATED LOSS OF RESPONSE BY MONITORING SERUM URIC ACID DURING PEGYLATED URICASE THERAPY | HORIZON THERAPEUTICS USA, INC. (US) | 2026-04-30 | — | — | US | claimed |
| US-20260109705-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2026-04-23 | — | — | US | claimed |
| EP-4724049-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | Catalent Ontario Limited (CA) | 2026-04-15 | — | — | EP | claimed |
| US-20260069593-A1 | METHODS FOR TREATING CANCER | AMGEN INC (US) | 2026-03-12 | — | — | US | claimed |
| EP-0879605-A2 | GLYCOSYL PRODRUG CONJUGATE WITH ENHANCED TOLERANCE | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-11-25 | — | — | EP | claimed |
| WO-1998048839-A1 | TOPICAL NASAL ANTIINFLAMMATORY COMPOSITIONS | WARNER-LAMBERT COMPANY (US) | 1998-11-05 | — | — | WO | claimed |
| WO-1998022114-A1 | A METHOD FOR PROMOTING TISSUE REPAIR | DUMEX-ALPHARMA A/S (DK) | 1998-05-28 | — | — | WO | claimed |
| WO-1998006394-A1 | TREATMENT OF UPPER AIRWAY ALLERGIC RESPONSES WITH A COMBINATION OF HISTAMINE RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 1998-02-19 | — | — | WO | claimed |
| EP-0759904-A1 | PROCESS AND DIASTEREOMERIC SALTS USEFUL FOR THE OPTICAL RESOLUTION OF RACEMIC ALPHA-[4-(1,1-DIMETHYLETHYL)PHENYL]-4-(HYDROXYDIPHENYLMETHYL)-1-PIPERIDINEBUTANOL AND DERIVATIVE COMPOUNDS | MERRELL PHARMACEUTICALS INC. (US) | 1997-03-05 | — | — | EP | claimed |
| EP-0701443-A1 | TERFENADINE METABOLITES AND THEIR OPTICALLY PURE ISOMERS FOR TREATING ALLERGIC DISORDERS | SEPRACOR, INC. (US) | 1996-03-20 | — | — | EP | claimed |
| WO-1995031436-A1 | PROCESS AND DIASTEREOMERIC SALTS USEFUL FOR THE OPTICAL RESOLUTION OF RACEMIC α-[4-(1,1-DIMETHYLETHYL)PHENYL]-4-(HYDROXYDIPHENYLMETHYL)-1-PIPERIDINEBUTANOL AND DERIVATIVE COMPOUNDS | MERRELL PHARMACEUTICALS INC. (US) | 1995-11-23 | — | — | WO | claimed |
| EP-0639976-A1 | USE OF TERFENADINE DERIVATIVES AS ANTIHISTAMINICS IN A HEPATICALLY IMPAIRED PATIENT | MERRELL PHARMACEUTICALS INC. (US) | 1995-03-01 | — | — | EP | claimed |
| WO-1994003170-A1 | TERFENADINE METABOLITES AND THEIR OPTICALLY PURE ISOMERS FOR TREATING ALLERGIC DISORDERS | SEPRACOR INC. (US) | 1994-02-17 | — | — | WO | claimed |
| WO-1993023047-A1 | USE OF TERFENADINE DERIVATIVES AS ANTIHISTAMINICS IN A HEPATICALLY IMPAIRED PATIENT | MERRELL DOW PHARMACEUTICALS INC. (US) | 1993-11-25 | — | — | WO | claimed |